Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats

✍ Scribed by L. Thomas; R. Grempler; M. Eckhardt; F. Himmelsbach; A. Sauer; T. Klein; P. Eickelmann; M. Mark

• Book ID: 109046244
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 541 KB
• Volume: 14
• Category: Article
• ISSN: 1462-8902
• DOI: 10.1111/j.1463-1326.2011.01518.x